KLF6 is ubiquitously expressed in human tissues and regulates many pathways such as differentiation, development, cellular proliferation, growth-related signal transduction, and apoptosis. We previously demonstrated that KLF6 expression is altered during liver carcinogenesis. More importantly, KLF6 invalidation results in cell cycle progression inhibition and apoptosis of liver cancer cells. On the other hand, enforced expression of KLF6 variant 2 (SV2) induces cancer cell death by apoptosis. Thus, we and others demonstrated that KLF6 and its splicing variants play a critical role in liver cancer. However, little is known on the mechanisms governing KLF6 expression in HCC. In the present work, we asked whether the 3' untranslated region (3'UTR) of the KLF6 mRNA may be responsible for regulation of KLF6 expression in HCC. We found that KLF6 mRNA stability was altered in liver-derived cell lines as compared to cervical cancer-derived cell lines and human embryonic fibroblasts. Interestingly, KLF6 mRNA was highly unstable in liver cancer-derived cell lines as compared to normal hepatocytes. We next cloned the KLF6 mRNA 3'UTR into luciferase-expressing vectors and found that gene expression and activity were strongly impaired in all liver-derived cell lines tested. In addition, we found that most the KLF6 3'UTR destabilisation activity resides between nt 1,835 and nt 2,615 of the KLF6 gene. Taken together, we provide the first steps towards better understanding of the regulation of KLF6 expression in HCC. Further work is needed to identify the factors that bind to KLF6 3'UTR to regulate its expression in liver cancer-derived cell lines.
References
[1]
Black, A.R.; Black, J.D.; Azizkhan-Clifford, J. Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 2001, 188, 143–160, doi:10.1002/jcp.1111.
[2]
Benzeno, S.; Narla, G.; Allina, J.; Cheng, G.Z.; Reeves, H.L.; Banck, M.S.; Odin, J.A.; Diehl, J.A.; Germain, D.; Friedman, S.L. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004, 64, 3885–3891, doi:10.1158/0008-5472.CAN-03-2818.
[3]
Rodríguez, E.; Aburjania, N.; Priedigkeit, N.M.; DiFeo, A.; Martignetti, J.A. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One 2010, 5, e12639.
[4]
Bieker, J.J. Krüppel-like factors: Three fingers in many pies. J. Biol. Chem. 2001, 276, 34355–34358, doi:10.1074/jbc.R100043200.
[5]
Kremer-Tal, S.; Reeves, H.L.; Narla, G.; Thung, S.N.; Schwartz, M.; Difeo, A.; Katz, A.; Bruix, J.; Bioulac-Sage, P.; Martignetti, J.A.; et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004, 40, 1047–1052, doi:10.1002/hep.20460.
[6]
Yamashita, K.; Upadhyay, S.; Osada, M.; Hoque, M.O.; Xiao, Y.; Mori, M.; Sato, F.; Meltzer, S.J.; Sidransky, D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, 2, 485–495, doi:10.1016/S1535-6108(02)00215-5.
[7]
Kremer-Tal, S.; Narla, G.; Chen, Y.; Hod, E.; DiFeo, A.; Yea, S.; Lee, J.-S.; Schwartz, M.; Thung, S.N.; Fiel, I.M.; et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol. 2007, 46, 645–654, doi:10.1016/j.jhep.2006.10.012.
[8]
Narla, G.; DiFeo, A.; Yao, S.; Banno, A.; Hod, E.; Reeves, H.L.; Qiao, R.F.; Camacho-Vanegas, O.; Levine, A.; Kirschenbaum, A.; et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005, 65, 5761–5768, doi:10.1158/0008-5472.CAN-05-0217.
[9]
Reeves, H.L.; Narla, G.; Ogunbiyi, O.; Haq, A.I.; Katz, A.; Benzeno, S.; Hod, E.; Harpaz, N.; Goldberg, S.; Tal-Kremer, S.; et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004, 126, 1090–1103, doi:10.1053/j.gastro.2004.01.005.
[10]
Ito, G.; Uchiyama, M.; Kondo, M.; Mori, S.; Usami, N.; Maeda, O.; Kawabe, T.; Hasegawa, Y.; Shimokata, K.; Sekido, Y. Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 2004, 64, 3838–3843, doi:10.1158/0008-5472.CAN-04-0185.
[11]
Cho, Y.G.; Kim, C.J.; Park, C.H.; Yang, Y.M.; Kim, S.Y.; Nam, S.W.; Lee, S.H.; Yoo, N.J.; Lee, J.Y.; Park, W.S. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 2005, 24, 4588–4590, doi:10.1038/sj.onc.1208670.
[12]
Camacho-Vanegas, O.; Narla, G.; Teixeira, M.S.; DiFeo, A.; Misra, A.; Singh, G.; Chan, A.M.; Friedman, S.L.; Feuerstein, B.G.; Martignetti, J.A. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int. J. Cancer 2007, 121, 1390–1395, doi:10.1002/ijc.22809.
[13]
Chen, H.; Liu, X.; Lin, J.; Chen, T.; Feng, Q.; Zeng, Y. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 2002, 21, 1047–1050.
[14]
Bureau, C.; Péron, J.M.; Bouisson, M.; Danjoux, M.; Selves, J.; Bioulac-Sage, P.; Balabaud, C.; Torrisani, J.; Cordelier, P.; Buscail, L.; et al. Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008, 23, 78–86, doi:10.1111/j.1440-1746.2007.05290.x.
[15]
Sirach, E.; Bureau, C.; Péron, J.M.; Pradayrol, L.; Vinel, J.P.; Buscail, L.; Cordelier, P. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ. 2007, 14, 1202–1210, doi:10.1038/sj.cdd.4402114.
[16]
Hanoun, N.; Bureau, C.; Diab, T.; Gayet, O.; Dusetti, N.; Selves, J.; Vinel, J.-P.; Buscail, L.; Cordelier, P.; Torrisani, J. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J. Hepatol. 2010, 53, 880–888, doi:10.1016/j.jhep.2010.04.038.
[17]
Bureau, C.; Hanoun, N.; Torrisani, J.; Vinel, J.-P.; Buscail, L.; Cordelier, P. Expression and function of Kruppel like-factors (KLF) in carcinogenesis. Curr. Genomics 2009, 10, 353–360, doi:10.2174/138920209788921010.
[18]
Song, J.; Kim, C.J.; Cho, Y.G.; Kim, S.Y.; Nam, S.W.; Lee, S.H.; Yoo, N.J.; Lee, J.Y.; Park, W.S. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2006, 21, 1286–1289, doi:10.1111/j.1440-1746.2006.04445.x.
[19]
Eberhardt, W.; Doller, A.; Akool, E.-S.; Pfeilschifter, J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol. Ther. 2007, 114, 56–73, doi:10.1016/j.pharmthera.2007.01.002.
[20]
Elkon, R.; Zlotorynski, E.; Zeller, K.I.; Agami, R. Major role for mRNA stability in shaping the kinetics of gene induction. BMC Genomics 2010, 11, e259, doi:10.1186/1471-2164-11-259.
[21]
Siepel, A.; Bejerano, G.; Pedersen, J.S.; Hinrichs, A.S.; Hou, M.; Rosenbloom, K.; Clawson, H.; Spieth, J.; Hillier, L.W.; Richards, S.; et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005, 15, 1034–1050, doi:10.1101/gr.3715005.
[22]
Xie, X.; Lu, J.; Kulbokas, E.J.; Golub, T.R.; Mootha, V.; Lindblad-Toh, K.; Lander, E.S.; Kellis, M. Systematic discovery of regulatory motifs in human promoters and 3'UTRs by comparison of several mammals. Nature 2005, 434, 338–345, doi:10.1038/nature03441.
[23]
ARE site. Available online: http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi (accessed on 25 November 2013).
[24]
Tsai, W.-C.; Hsu, S.-D.; Hsu, C.-S.; Lai, T.-C.; Chen, S.-J.; Shen, R.; Huang, Y.; Chen, H.-C.; Lee, C.-H.; Tsai, T.-F.; et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 2012, 122, 2884–2897, doi:10.1172/JCI63455.
[25]
Mignone, F.; Gissi, C.; Liuni, S.; Pesole, G. Untranslated regions of mRNAs. Genome Biol. 2002, 3, 1–10.
[26]
Vázquez-Chantada, M.; Fernández-Ramos, D.; Embade, N.; Martínez-Lopez, N.; Varela-Rey, M.; Woodhoo, A.; Luka, Z.; Wagner, C.; Anglim, P.P.; Finnell, R.H.; et al. HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology 2010, 138, 1943–1953, doi:10.1053/j.gastro.2010.01.032.
[27]
Humeau, M.; Torrisani, J.; Cordelier, P. miRNA in clinical practice: Pancreatic cancer. Clin. Biochem. 2013, 46, 933–936, doi:10.1016/j.clinbiochem.2013.03.019.
[28]
Zhang, X.; Nie, Y.; Du, Y.; Cao, J.; Shen, B.; Li, Y. MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumor Biol. 2012, 33, 1589–1597, doi:10.1007/s13277-012-0414-3.
